Product Information
METHYLPHENIDATE 20 MG/9 HR PATCH is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $6.6092 per EA under NDC 00378826293. Its NADAC has been published 168 times since Jul 19, 2023.
FDA first approved this application on Mar 14, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.2 mg/h
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378826293
Classification
Generic
Dosage Form
PATCH
Route
TRANSDERMAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATEApproval Type
Generic (ANDA)
FDA Application
ANDA206497FDA Approved
3/14/2022
TE Code
AB
On Market Since
6/27/2022
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE 20 MG/9 HR PATCH has been published 168 times since Jul 19, 2023, and over the history we have for it it has declined 42.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.6092 per EA |
|---|---|
| All-time high | $12.4843 (Mar 13, 2024) |
| All-time low | $6.6092 (Sep 23, 2026) |
| 52-week high | $10.8599 |
| 52-week low | $6.6092 |
| Median price | $9.5983 |
| Average price | $9.9332 |
| Largest weekly change | -9.1% (Mar 20, 2024) |
| Weeks tracked | 168 |
| Tracking since | Jul 19, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methylphenidate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE 20 MG/9 HR PATCH?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE 20 MG/9 HR PATCH, manufactured by Mylan Pharmaceuticals Inc., is $6.6092 per EA (NDC 00378826293), effective Sep 30, 2026.
How has the price of METHYLPHENIDATE 20 MG/9 HR PATCH changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE 20 MG/9 HR PATCH has declined 42.6%. It has been tracked across 168 weekly CMS publications since Jul 19, 2023.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE 20 MG/9 HR PATCH?
Since Jul 19, 2023, the NADAC for METHYLPHENIDATE 20 MG/9 HR PATCH has ranged from a low of $6.6092 (Sep 23, 2026) to a high of $12.4843 (Mar 13, 2024), with a median of $9.5983 per EA.
Are there cheaper alternatives to METHYLPHENIDATE 20 MG/9 HR PATCH?
No other NADAC-published product currently shares the active ingredient and strength of METHYLPHENIDATE 20 MG/9 HR PATCH in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures METHYLPHENIDATE 20 MG/9 HR PATCH?
METHYLPHENIDATE 20 MG/9 HR PATCH (NDC 00378826293) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.